Zealand Pharma AS
Company Profile
Business description
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
Contact
Sydmarken 11
SoborgDK-2860
DNKT: +45 88773600
E: info@zealandpharma.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
481
Zealand Pharma AS News & Analysis
stocks
2 companies poised to capitalize on the rise of GLP-1 drugs
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,745.30 | 66.70 | 0.77% |
| CAC 40 | 7,743.92 | 17.72 | 0.23% |
| DAX 40 | 22,636.91 | 16.95 | -0.07% |
| Dow JONES (US) | 46,124.06 | 84.41 | -0.18% |
| FTSE 100 | 9,965.16 | 71.01 | 0.72% |
| HKSE | 25,269.36 | 205.65 | 0.82% |
| NASDAQ | 21,761.89 | 184.87 | -0.84% |
| Nikkei 225 | 53,749.62 | 1,497.34 | 2.87% |
| NZX 50 Index | 12,929.30 | 227.55 | 1.79% |
| S&P 500 | 6,556.37 | 24.63 | -0.37% |
| S&P/ASX 200 | 8,534.30 | 45.70 | 0.54% |
| SSE Composite Index | 3,931.84 | 50.56 | 1.30% |